RxDoctor Payments Data

James Gordon, MD

Pain Medicine · Monroe, LANPI 1528149820

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,774 of the $7,449 with a category attached, or 64.1%. 23 manufacturers reported payments, led by Saluda Medical Americas, Inc. at 40.4% of the total. 2025 is the largest year on record at $3,556, more than ten times the $353 reported in 2019.

$7,449in general payments, 2019–2025

Across 135 payments — averaging $55.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$3K
  • Boston Scientific$1K
  • Camber Spine Technologies LLC$634
  • Surgentec$481
  • Nevro Corp.$348
  • Amgen$300
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$2,67536%
  • Food & beverage$4,77464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,449 in reported general payments places this provider in the 70th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$696,364
Medicare patients
1,102
Services billed
8,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen5,278$123,142
OxycontinOxycodone Hcl53$48,433
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,504$41,846
Gabapentin1,737$17,267
Fentanyl168$15,442
LinzessLinaclotide25$13,081
MovantikNaloxegol Oxalate26$10,026
Tramadol Hcl978$7,017
Morphine Sulfate ErMorphine Sulfate195$6,043
Pregabalin540$5,909
Tizanidine Hcl809$5,093
Diclofenac Sodium199$5,082
Cyclobenzaprine Hcl602$4,365
Oxycodone Hcl230$4,144
Lidocaine28$3,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$44$13,08125 claims
Redhill Biopharma Inc.Movantik$11$10,02626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 97 pain medicine providers in Louisiana.

Other pain medicine in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →